Cargando…

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates

BACKGROUND: Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure—driven by high prices—will be unsustainable unless further reforms are enacted. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espin, Jaime, Schlander, Michael, Godman, Brian, Anderson, Pippa, Mestre-Ferrandiz, Jorge, Borget, Isabelle, Hutchings, Adam, Flostrand, Steven, Parnaby, Adam, Jommi, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244625/ https://www.ncbi.nlm.nih.gov/pubmed/30088251 http://dx.doi.org/10.1007/s40258-018-0419-1

Ejemplares similares

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Argumentación rebatible : modelos y aplicaciones
por: Bodanza, Gustavo Adrián
Publicado: (2011)

Claim for Rebate of Spirit Duty
por: Churchfield, Jas. M.
Publicado: (1917)

Implications of drugs with rebate in Europe
por: Bonetti, Andrea, et al.
Publicado: (2021)

Physicians’ Rebate Check-Book
Publicado: (1892)

Premium Rebates and the Quiet Consensus on Market Reform for Medicare
por: Feldman, Roger, et al.
Publicado: (2001)

Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests
por: Del Llano, Juan, et al.
Publicado: (2021)

Paediatric genomic testing: Navigating medicare rebatable genomic testing
por: Sachdev, Rani, et al.
Publicado: (2021)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment
por: Schlander, Michael, et al.
Publicado: (2021)

Footing the bill: the introduction of Medicare Benefits Schedule rebates for podiatry services in Australia
por: Short, Anthony J
Publicado: (2009)

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019
por: Plummer, Elizabeth, et al.
Publicado: (2022)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021)

An exploration of rollover protective structures (ROPS) rebate program media coverage: strategies for implementation and sustainment
por: Tinc, Pamela J., et al.
Publicado: (2019)

Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs
por: Wong, William Bruce, et al.
Publicado: (2023)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Delay discounting, probability discounting, and interdental cleaning frequency
por: DeFulio, Anthony, et al.
Publicado: (2022)

Delay Discounting in Gambling Disorder: Implications in Treatment Outcome
por: Mena-Moreno, Teresa, et al.
Publicado: (2022)

Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool
por: Vivas-Consuelo, David, et al.
Publicado: (2014)

Impact of the Medicare Benefits Schedule Rebate (MBSR) freeze on General Practice (GP) use: multivariable regression analysis
por: Mudiyanselage, Shalika Bohingamu, et al.
Publicado: (2023)

Erratum to: Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool
por: Vivas-Consuelo, David, et al.
Publicado: (2017)

Do the Powerful Discount the Future Less? The Effects of Power on Temporal Discounting
por: Duan, Jinyun, et al.
Publicado: (2017)

Discounting in Economic Evaluations
por: Attema, Arthur E., et al.
Publicado: (2018)

Values in Time Discounting
por: Heilmann, Conrad
Publicado: (2017)

Social discounting of pain
por: Story, Giles W., et al.
Publicado: (2020)

The globalizability of temporal discounting
por: Ruggeri, Kai, et al.
Publicado: (2022)

Discounting of reward sequences: a test of competing formal models of hyperbolic discounting
por: Zarr, Noah, et al.
Publicado: (2014)

The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study
por: Armeni, Patrizio, et al.
Publicado: (2015)

Pharmaceutical Expenditure and Burden of Non-communicable Diseases in Serbia
por: Kovacevic, Aleksandra, et al.
Publicado: (2016)

Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
por: Hernandez, Inmaculada, et al.
Publicado: (2020)

Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
por: Yeung, Kai, et al.
Publicado: (2021)

Over-exploitation of natural resources is followed by inevitable declines in economic growth and discount rate
por: Lampert, Adam
Publicado: (2019)

Generalized Zero-Adjusted Models to Predict Medical Expenditures
por: Xu, Xin, et al.
Publicado: (2021)

Physical and cognitive effort discounting across different reward magnitudes: Tests of discounting models
por: Białaszek, Wojciech, et al.
Publicado: (2017)

Using the Advocacy Coalition Framework to understand EU pharmaceutical policy
por: Brooks, Eleanor
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4pd1j74ggml268969mv8oridp6